Joint research
(target/mechanism validation)

Joint development
(preclinical to clinical)

Indication expansion

Combination therapy development

CMC/Production

Regional commercialization

Licensing in/out
(by global/regional scope and indication)

Co-development

Option-to-license

Platform partnerships

Platform technology and data

Candidates (or leads)

Preclinical PoC package

Biomarker and patient selection strategy (when available)

Clinical development capabilities, including design and operations

CMC, scale-up, and GMP manufacturing capabilities

Global and regional commercialization infrastructure

Partner assets suitable for combination therapy

Co-investment option structures